• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Have You Heard? A new treatment option for feline cytauxzoonosis (script)

May 1, 2011
Avi Blake, DVM

One of the scariest tick-borne pathogens is Cytauxzoon felis.

One of the scariest tick-borne pathogens is Cytauxzoon felis. While cats with cytauxzoonosis have been known to survive the illness with or without specific drug therapy, this disease is generally considered fatal. No antiprotozoal protocol has been successful in altering the course of this disease, but supportive care and treatment with imidocarb dipropionate has become the accepted therapy.

Recently, a study was conducted to compare the efficacy of two treatment options—a combination of atovaquone and azithromycin or imidocarb dipropionate alone. In a preliminary study, use of this combination of an antimalarial and antibacterial drug was encouraging.

David De Lossy/Getty Images

Advertisement

Eighty cats with acute cytauxzoonosis from a variety of veterinary clinics in five endemic states participated in this study. Most of the cats were young adults with outdoor access and presented with vague clinical signs of lethargy and anorexia.

After diagnosis, each cat was randomly assigned to one of two treatment groups. One group was treated for 10 days with atovaquone (15 mg/kg orally three times daily) and azithromycin (10 mg/kg orally once daily). Cats in the imidocarb group were pretreated with subcutaneous atropine and 15 minutes later received an intramuscular injection of imidocarb dipropionate at a dose of 3.5 mg/kg. The injection procedure was repeated seven days later. Treating veterinarians were at liberty to provide supportive care and other concomitant treatments. The cats were discharged when they were afebrile and eating voluntarily.

All therapies were recorded, and medical records were provided to the study authors. Anticoagulated blood samples were used for PCR identification of C. felis. Parasitemia was quantified, and the specific pathogens were genotyped. The primary endpoint for each participant was either survival to discharge, or death.

The findings revealed that 60% of the cats treated with the atovaquone-azithromycin combination survived, as compared with only 26% of those in the imidocarb treatment group. Another interesting finding was that regardless of treatment, cats with lower parasitemia were more likely to survive, as were cats with higher white blood cell counts and lower total bilirubin concentrations. However, the authors of this study caution that because of the small study size, these parameters cannot be used as predictors of outcome. The results also showed that the cats were infected with a variety of pathogen genotypes, and several individuals were infected with multiple isolates.

The results of this study indicate that treatment with atovaquone and azithromycin improves survival to discharge for cats with acute cytauxzoonosis, although mortality remains high. As noted by the authors, the high rate of mortality associated with this infection should prompt veterinarians to focus their efforts on prevention by minimizing cats' exposure to ticks.

Cohn LA, Birkenheuer AH, Brunker JD, et al. Efficacy of atovaquone and azithromycin or imidocarb dipropionate in cats with acute cytauxzoonosis. J Vet Intern Med 2011;25:55-60.

Related Content:

ParasitologyFeline Medicine
FDA approves generic drug for managing allergic dermatitis in cats
FDA approves generic drug for managing allergic dermatitis in cats
Unusual parasite strain kills 4 California sea otters
Unusual parasite strain kills 4 California sea otters
Chronic feline pain from all perspectives
Chronic feline pain from all perspectives

Advertisement

Latest News

To refer or to not refer

Advice panel for women interested in the veterinary field

AVMA president set to testify before Congress

New Hawaii-based pet CBD brand launches

View More Latest News
Advertisement